Integrated Molecular Pathology, National Cancer Research Institute, Genova, Italy.
ENT Department, University of Genova, Italy.
Cancer Lett. 2011 Aug 1;307(1):37-46. doi: 10.1016/j.canlet.2011.03.013. Epub 2011 Apr 9.
Survival after diagnosis of laryngeal cancer has not improved over the last 20 years. Selection of patients for radio- and chemotherapy or surgery or follow-up strategies based on a prognostic classifier could improve survival without unduly extending radical surgery. We performed microarray gene expression analysis and developed a four-gene classifier for laryngeal cancer using Prediction Analysis of Microarray and leave-one-out cross validation. A four-gene classifier containing the non-coding gene H19, the histone HIST1H3F and the two small nucleolar RNAs, SNORA16A and SNORD14C was developed that assigns cases to low and high risk classes. The high risk class has a relative risk of 6.5 (CI=1.817-23.258, Fisher exact test p<0.0001). The maternally imprinted gene H19 is the top classifier gene.
在过去的 20 年中，喉癌患者的生存率并没有提高。通过预后分类器选择接受放化疗、手术或随访策略的患者，可以在不过度扩大根治性手术的前提下提高生存率。我们使用基因芯片表达分析和留一法交叉验证，开发了一个用于喉癌的四基因分类器。该分类器包含非编码基因 H19、组蛋白 HIST1H3F 以及两个小核仁 RNA，SNORA16A 和 SNORD14C，可将病例分为低风险和高风险两类。高风险类别的相对风险为 6.5（CI=1.817-23.258，Fisher 精确检验 p<0.0001）。母源性印记基因 H19 是顶级分类器基因。
